影响糖尿病新生血管性青光眼患者接受艾哈迈德青光眼瓣膜植入术(无论之前是否进行过玻璃体旁切除术)效果的因素。

Beyoglu Eye Journal Pub Date : 2024-06-01 eCollection Date: 2024-01-01 DOI:10.14744/bej.2024.64497
Hatice Tekcan, Serhat Imamoglu, Yucel Ozturk
{"title":"影响糖尿病新生血管性青光眼患者接受艾哈迈德青光眼瓣膜植入术(无论之前是否进行过玻璃体旁切除术)效果的因素。","authors":"Hatice Tekcan, Serhat Imamoglu, Yucel Ozturk","doi":"10.14744/bej.2024.64497","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>The aim of this study was to compare the outcomes of Ahmed glaucoma valve implantation (AGVI) in neovascular glaucoma (NVG) due to proliferative diabetic retinopathy (PDR) with or without a pars plana vitrectomy (PPV) history and to analyze the factors affecting surgical failure.</p><p><strong>Methods: </strong>Patients with NVG secondary to PDR undergoing AGVI at a single center were reviewed retrospectively. The surgical failure rates and post-operative complications were compared between eyes with (PPV-AGVI group) and without previous PPV (AGVI group). Failure was defined as loss of light perception or intraocular pressure (IOP) >17 mmHg despite maximum medication, or need of additional intervention for IOP control or for the management of complications. Survival analysis was investigated by Kaplan-Meier test. The possible factors for failure were analyzed with logistic regression analysis.</p><p><strong>Results: </strong>The failure rates were 21.9% during the mean follow-up of 27.56±15.38 months and 14.3% during 23.63±12.38 months, in PPV-AGVI group (n=32) and in AGVI group (n=49), respectively (p=0.37). The frequency of complications and surgical intervention need for management of post-operative complications was similar between groups (p>0.05). There was no significant difference in survival analysis (p=0.13). The history of intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection before AGVI was significantly associated with failure (odds ratio = 26.941, p=0.02).</p><p><strong>Conclusion: </strong>The results of AGVI performed with long scleral tunnel technique were comparable in terms of failure rates, between NVG patients with and without previous diabetic vitrectomy. The only significant factor for failure was intravitreal anti-VEGF pre-treatment. This may be related to the necessity of anti-VEGF therapy in aggressive PDR, and also, anti-VEGF agents may increase fibrosis in the anterior chamber angle.</p>","PeriodicalId":8740,"journal":{"name":"Beyoglu Eye Journal","volume":"9 2","pages":"76-85"},"PeriodicalIF":0.0000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11156472/pdf/","citationCount":"0","resultStr":"{\"title\":\"Factors Affecting the Results of Ahmed Glaucoma Valve Implantation in Diabetic Neovascular Glaucoma With or Without Previous Pars Plana Vitrectomy.\",\"authors\":\"Hatice Tekcan, Serhat Imamoglu, Yucel Ozturk\",\"doi\":\"10.14744/bej.2024.64497\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>The aim of this study was to compare the outcomes of Ahmed glaucoma valve implantation (AGVI) in neovascular glaucoma (NVG) due to proliferative diabetic retinopathy (PDR) with or without a pars plana vitrectomy (PPV) history and to analyze the factors affecting surgical failure.</p><p><strong>Methods: </strong>Patients with NVG secondary to PDR undergoing AGVI at a single center were reviewed retrospectively. The surgical failure rates and post-operative complications were compared between eyes with (PPV-AGVI group) and without previous PPV (AGVI group). Failure was defined as loss of light perception or intraocular pressure (IOP) >17 mmHg despite maximum medication, or need of additional intervention for IOP control or for the management of complications. Survival analysis was investigated by Kaplan-Meier test. The possible factors for failure were analyzed with logistic regression analysis.</p><p><strong>Results: </strong>The failure rates were 21.9% during the mean follow-up of 27.56±15.38 months and 14.3% during 23.63±12.38 months, in PPV-AGVI group (n=32) and in AGVI group (n=49), respectively (p=0.37). The frequency of complications and surgical intervention need for management of post-operative complications was similar between groups (p>0.05). There was no significant difference in survival analysis (p=0.13). The history of intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection before AGVI was significantly associated with failure (odds ratio = 26.941, p=0.02).</p><p><strong>Conclusion: </strong>The results of AGVI performed with long scleral tunnel technique were comparable in terms of failure rates, between NVG patients with and without previous diabetic vitrectomy. The only significant factor for failure was intravitreal anti-VEGF pre-treatment. This may be related to the necessity of anti-VEGF therapy in aggressive PDR, and also, anti-VEGF agents may increase fibrosis in the anterior chamber angle.</p>\",\"PeriodicalId\":8740,\"journal\":{\"name\":\"Beyoglu Eye Journal\",\"volume\":\"9 2\",\"pages\":\"76-85\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11156472/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Beyoglu Eye Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14744/bej.2024.64497\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Beyoglu Eye Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14744/bej.2024.64497","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

研究目的本研究旨在比较有或无玻璃体旁切除术(PPV)病史的增殖性糖尿病视网膜病变(PDR)所致新生血管性青光眼(NVG)患者接受艾哈迈德青光眼瓣膜植入术(AGVI)的疗效,并分析影响手术失败的因素:方法:对在一个中心接受AGVI手术的继发于PDR的NVG患者进行回顾性研究。比较了有PPV-AGVI组和无PPV组(AGVI组)的手术失败率和术后并发症。手术失败的定义是:在最大限度用药后仍丧失光感或眼压(IOP)>17 mmHg,或需要额外干预以控制眼压或处理并发症。生存分析采用卡普兰-梅耶(Kaplan-Meier)检验法。采用逻辑回归分析法对可能导致失败的因素进行了分析:PPV-AGVI组(32人)和AGVI组(49人)的平均随访时间分别为(27.56±15.38)个月和(23.63±12.38)个月,失败率分别为21.9%和14.3%(P=0.37)。两组的并发症发生率和术后并发症处理所需的手术干预相似(P>0.05)。生存率分析无明显差异(P=0.13)。AGVI术前曾在玻璃体内注射抗血管内皮生长因子(anti-VEGF)与手术失败有显著相关性(几率=26.941,P=0.02):使用长巩膜隧道技术进行 AGVI 的失败率在既往接受过糖尿病玻璃体切除术和未接受过糖尿病玻璃体切除术的 NVG 患者之间具有可比性。唯一导致失败的重要因素是静脉内抗 VEGF 预处理。这可能与侵袭性 PDR 必须使用抗血管内皮生长因子治疗有关,而且抗血管内皮生长因子药物可能会增加前房角的纤维化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Factors Affecting the Results of Ahmed Glaucoma Valve Implantation in Diabetic Neovascular Glaucoma With or Without Previous Pars Plana Vitrectomy.

Objectives: The aim of this study was to compare the outcomes of Ahmed glaucoma valve implantation (AGVI) in neovascular glaucoma (NVG) due to proliferative diabetic retinopathy (PDR) with or without a pars plana vitrectomy (PPV) history and to analyze the factors affecting surgical failure.

Methods: Patients with NVG secondary to PDR undergoing AGVI at a single center were reviewed retrospectively. The surgical failure rates and post-operative complications were compared between eyes with (PPV-AGVI group) and without previous PPV (AGVI group). Failure was defined as loss of light perception or intraocular pressure (IOP) >17 mmHg despite maximum medication, or need of additional intervention for IOP control or for the management of complications. Survival analysis was investigated by Kaplan-Meier test. The possible factors for failure were analyzed with logistic regression analysis.

Results: The failure rates were 21.9% during the mean follow-up of 27.56±15.38 months and 14.3% during 23.63±12.38 months, in PPV-AGVI group (n=32) and in AGVI group (n=49), respectively (p=0.37). The frequency of complications and surgical intervention need for management of post-operative complications was similar between groups (p>0.05). There was no significant difference in survival analysis (p=0.13). The history of intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection before AGVI was significantly associated with failure (odds ratio = 26.941, p=0.02).

Conclusion: The results of AGVI performed with long scleral tunnel technique were comparable in terms of failure rates, between NVG patients with and without previous diabetic vitrectomy. The only significant factor for failure was intravitreal anti-VEGF pre-treatment. This may be related to the necessity of anti-VEGF therapy in aggressive PDR, and also, anti-VEGF agents may increase fibrosis in the anterior chamber angle.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
42
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信